These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28093142)

  • 1. Re: Comprehensive Genomic Profiling of 295 Cases of Clinically Advanced Urothelial Carcinoma of the Urinary Bladder Reveals a High Frequency of Clinically Relevant Genomic Alterations.
    Chang SS
    J Urol; 2017 Feb; 197(2):319. PubMed ID: 28093142
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Comprehensive Genomic Profiling of 295 Cases of Clinically Advanced Urothelial Carcinoma of the Urinary Bladder Reveals a High Frequency of Clinically Relevant Genomic Alterations.
    Liedberg F
    Eur Urol; 2016 Aug; 70(2):400-1. PubMed ID: 27353966
    [No Abstract]   [Full Text] [Related]  

  • 3. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Occult Metastases in Pelvic Lymphadenectomy Specimens from Patients with Urothelial Carcinoma of the Bladder.
    Chang SS
    J Urol; 2017 May; 197(5):1218-1219. PubMed ID: 29539891
    [No Abstract]   [Full Text] [Related]  

  • 5. Genomics in upper tract urothelial carcinoma.
    Kammerer-Jacquet SF; Mathieu R; Peyronnet B; Rioux-Leclercq N; Bensalah K
    Curr Opin Urol; 2017 Jan; 27(1):35-40. PubMed ID: 27584028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis from the National Cancer Data Base.
    Mathieu R; Peyronnet B; Bensalah K
    Eur Urol; 2016 Nov; 70(5):894. PubMed ID: 27497763
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Efficacy of High-intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis from the National Cancer Data Base.
    Woldu SL; Lotan Y
    Eur Urol; 2016 Nov; 70(5):893. PubMed ID: 27498598
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis from the National Cancer Data Base.
    Chang SS
    J Urol; 2018 Jun; 199(6):1396. PubMed ID: 29783592
    [No Abstract]   [Full Text] [Related]  

  • 9. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
    Sethakorn N; O'Donnell PH
    BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
    Black PC; Seiler R
    Eur Urol; 2016 Dec; 70(6):1076. PubMed ID: 27567209
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Advanced Small Cell Carcinoma of the Bladder: Clinical Characteristics, Treatment Patterns and Outcomes in 960 Patients and Comparison with Urothelial Carcinoma.
    Chang SS
    J Urol; 2017 Jun; 197(6):1440. PubMed ID: 28505896
    [No Abstract]   [Full Text] [Related]  

  • 12. Genomics and Therapeutic Decisions in Urothelial Malignancies.
    Vaishampayan U
    J Oncol Pract; 2019 Aug; 15(8):431-432. PubMed ID: 31404515
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Laguna MP
    J Urol; 2016 Jun; 195(6):1719. PubMed ID: 27191062
    [No Abstract]   [Full Text] [Related]  

  • 14. Extravesical Pagetoid Spread of Urothelial Carcinoma in Situ. A Report of Five Cases.
    Akgul M; Bomeisl PB; MacLennan GT
    Anal Quant Cytopathol Histpathol; 2015 Dec; 37(6):364-8. PubMed ID: 26860012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7.
    Mullane SA; Bellmunt J
    Eur Urol; 2016 Sep; 70(3):e71. PubMed ID: 26852077
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
    Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
    Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urothelial cancer of the urinary bladder: can lessons learned be applied to the upper urinary tract?
    Krabbe LM; Hutchinson RC; Margulis V
    Minerva Urol Nefrol; 2016 Aug; 68(4):396-408. PubMed ID: 26990295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial Comment on Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes.
    Mehrazin R
    J Urol; 2020 Sep; 204(3):413. PubMed ID: 32762316
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: HER2 as a Target in Invasive Urothelial Carcinoma.
    Chang SS
    J Urol; 2016 Dec; 196(6):1637-1639. PubMed ID: 27845103
    [No Abstract]   [Full Text] [Related]  

  • 20. An update on the molecular pathology of urinary bladder tumors.
    Yousef PG; Gabril MY
    Pathol Res Pract; 2018 Jan; 214(1):1-6. PubMed ID: 29254798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.